Skip to content
Clinical Trials – home
CroatiaBack to Croatia

Clinical trials in Vinkovci – page 7

88 clinical trials in Vinkovci, Croatia. Every trial is listed in the EU Clinical Trials Register and updated daily.

CroatiaOur site in CroatiaKlinicka-Ispitivanja.hr(opens in a new tab)
Vinkovci at a glance
88
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

88 trials in Vinkovci

Open in trial search

Study of OPT-302 and Aflibercept for Patients with Wet Age-related Macular Degeneration

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Opthea Limited

Hidradenitis

Not recruiting

Study of lutikizumab compared to placebo in adults and adolescents (age 12 and older) with moderate to severe Hidradenitis Suppurativa

Investigational
Countries:CroatiaCroatia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lutikizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Effectiveness and Safety of Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Hepatic cirrhosis

Not recruiting

Study on the Effects of Human Serum Albumin on Survival in Patients with Severe Acute-On-Chronic Liver Failure

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Human Serum Albumin
  • Sponsor:Instituto Grifols S.A.

Study Comparing RBS-001 and Aflibercept for Patients with Neovascular Age-Related Macular Degeneration

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Rophibio Inc.

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:CroatiaCroatia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years
  • Substances:Charcoal, Activated
  • Sponsor:Novartis Pharma AG

Colitis ulcerative

Not recruiting

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:CroatiaCroatia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years
  • Substances:Charcoal, Activated
  • Sponsor:Novartis Pharma AG

Constipation

Not recruiting

Study on Linaclotide for Treating Functional Constipation in Children Aged 6 Months to Less Than 2 Years

Registered drug
Countries:CroatiaCroatia
  • Participants:0–17 years
  • Substances:Linaclotide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Colitis ulcerative

Not recruiting

Study on the Effects of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Study on the Safety of Avacincaptad Pegol for Patients with Geographic Atrophy Who Completed a Previous Study

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Avacincaptad Pegol
  • Sponsor:Astellas Pharma Global Development Inc.

Other cities in Croatia

The busiest research cities in the country

All 26 cities in Croatia

Clinical research in Vinkovci

What the registry says about research in the country

01 Cardiovascular Research

Groundbreaking clinical trials focusing on atherosclerotic cardiovascular disease (ASCVD) prevention are underway. These studies aim to evaluate innovative therapeutic approaches for reducing major cardiovascular events in high-risk patients.

  • Primary Prevention Studies
  • Cardiovascular Risk Management
  • Major Adverse Cardiovascular Events

Research initiatives are exploring new treatment options to prevent serious cardiovascular complications, including coronary events, myocardial infarction, and ischemic stroke in at-risk populations.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.